CRDFCardiff Oncology, Inc.

$133M

FY 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$244,632-35.3% YoY

Gross Profit

$244,632100.0% margin

Operating Income

-$17M-6817.8% margin

Net Income

-$16M-6709.7% margin

EPS (Diluted)

$-2.70

Cash Flow

Operating Cash Flow

-$13M

Free Cash Flow

-$13M

Stock-Based Comp.

$885,000

Balance Sheet

Total Assets

$13M

Total Liabilities

$6M

Stockholders' Equity

$7M

Cash & Equivalents

$10M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$244,632	$378,000	-35.3%
Gross Profit	$244,632	-$219,000	+211.7%
Operating Income	-$17M	-$17M	+2.2%
Net Income	-$16M	-$16M	+0.3%

CRDF FY 2019 Earnings — Cardiff Oncology, Inc. Revenue & Financial Results | Market Cap Arena